PT  - JOURNAL ARTICLE
AU  - YAMAGUCHI, TOSHIFUMI
AU  - YOSHIDA, MOTOKI
AU  - TAIRA, KOICHI
AU  - TOKUNAGA, SHINYA
AU  - KATO, TAKESHI
AU  - NAKAMURA, MASATO
AU  - SUGIMOTO, NAOTOSHI
AU  - FUMITA, SOICHI
AU  - YASUI, MASAYOSHI
AU  - MIYAKE, YASUHIRO
AU  - KAWAKAMI, HISATO
AU  - KUROKAWA, YUKINORI
AU  - SHIMOKAWA, TOSHIO
AU  - SATOH, TAROH
TI  - Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102
AID  - 10.21873/invivo.13950
DP  - 2025 May 01
TA  - In Vivo
PG  - 1505--1513
VI  - 39
IP  - 3
4099  - http://iv.iiarjournals.org/content/39/3/1505.short
4100  - http://iv.iiarjournals.org/content/39/3/1505.full
SO  - In Vivo2025 May 01; 39
AB  - Background/Aim: The combination of capecitabine and bevacizumab is a standard first-line chemotherapy regimen for vulnerable patients with unresectable colorectal cancer. However, the safety and efficacy of this regimen in Japanese patients have not been sufficiently investigated.Patients and Methods: This phase II study included patients aged ≥76 years or those aged 65-75 years who were unsuitable for intensive chemotherapy. Capecitabine at 2000 mg/m2/day (days 1-14) plus bevacizumab at 7.5 mg/kg (day 1) were administered every 3 weeks. The primary endpoint was progression-free survival. Secondary endpoints included overall survival, response rate, disease control rate, and toxicities.Results: Thirty-six patients were enrolled between July 2011 and July 2014, of whom 33 were included in the analysis. The median patient age was 78 years (range=67-86 years). A total of 28 patients had a performance status of 0 or 1, and five of 2. The median progression-free and overall survival were 10.3 (95% confidence interval=9.2-15.4) and 27.9 (95% confidence interval=24.2-50.1) months, respectively. The response and disease control rates were 30.3% and 91.0%, respectively. The major grade 3 or 4 toxicities were hypertension (n=12, 36%) and hand-foot syndrome (n=4, 12%). One patient experienced a grade 4 gastrointestinal perforation.Conclusion: The combination of capecitabine and bevacizumab demonstrated favorable efficacy and tolerability in Japanese patients with metastatic colorectal cancer who were unsuitable for intensive chemotherapy.